Centene Corp. (CNC) Stock Forecast
Data as of Sep 16, 2026Healthcare · Current price $67.41 (—)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Ann Hynes | Mizuho Securities | $41.00 | -39.2% |
| Feb 18, 2026 | Stephen Baxter | Wells Fargo | $44.00 | -34.7% |
| Nov 4, 2025 | Andrew Mok | Barclays | $44.00 | -34.7% |
| Oct 30, 2025 | Michael Wiederhorn | Oppenheimer | $45.00 | -33.2% |
| Oct 30, 2025 | Scott Fidel | Goldman Sachs | $38.00 | -43.6% |
| Sep 4, 2025 | Andrew Mok | Barclays | $33.00 | -51.0% |
| Jul 15, 2025 | Michael Wiederhorn | Oppenheimer | $51.00 | -24.3% |
| Apr 15, 2025 | Michael Ha | Robert W. Baird | $69.00 | +2.4% |
| Oct 29, 2024 | Andrew Mok | Barclays | $91.00 | +35.0% |
| Sep 10, 2024 | David Windley | Jefferies | $72.00 | +6.8% |
| Sep 5, 2024 | Andrew Mok | Barclays | $97.00 | +43.9% |
| Jul 11, 2024 | David Windley | Jefferies | $83.00 | +23.1% |
| Apr 29, 2024 | David Windley | Jefferies | $90.00 | +33.5% |
| Apr 15, 2024 | Stephen Baxter | Wells Fargo | $93.00 | +38.0% |
| Aug 26, 2022 | Stephen Baxter | Wells Fargo | $99.00 | +46.9% |
| Jul 26, 2022 | David MacDonald | Truist Financial | $102.00 | +51.3% |
| Jan 5, 2022 | David S Macdonald | Truist Financial | $96.00 | +42.4% |
| Dec 17, 2021 | Ricky Goldwasser | Morgan Stanley | $109.00 | +61.7% |
| Dec 14, 2021 | Nathan Rich | Goldman Sachs | $83.00 | +23.1% |
| Dec 13, 2021 | Kevin Fischbeck | Bank of America Securities | $93.00 | +38.0% |
Top Analysts Covering CNC
CNC vs Sector & Market
| Metric | CNC | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.50 | 2.25 | 2.42 |
| Analyst Count | 30 | 8 | 18 |
| Target Upside | +3.1% | +16187.2% | +19.5% |
| P/E Ratio | -3.79 | 3.79 | 38.67 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $185.91B | $188.83B | $191.48B | 12 |
| 2027-03-31 | $46.50B | $47.69B | $48.57B | 4 |
| 2027-06-30 | $46.41B | $47.59B | $48.47B | 4 |
| 2027-09-30 | $47.64B | $48.85B | $49.75B | 5 |
| 2027-12-31 | $47.57B | $48.78B | $49.68B | 4 |
| 2028-03-31 | $47.84B | $49.06B | $49.96B | 3 |
| 2028-06-30 | $48.08B | $49.31B | $50.22B | 3 |
| 2028-09-30 | $49.27B | $50.53B | $51.46B | 5 |
| 2028-12-31 | $49.86B | $51.13B | $52.07B | 3 |
| 2029-12-31 | $195.10B | $201.23B | $207.07B | 4 |
| 2030-12-31 | $204.53B | $210.95B | $217.08B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $2.96 | $3.02 | $3.06 | 11 |
| 2027-03-31 | $2.35 | $2.43 | $2.49 | 4 |
| 2027-06-30 | $1.36 | $1.40 | $1.44 | 5 |
| 2027-09-30 | $0.44 | $0.46 | $0.47 | 8 |
| 2027-12-31 | $-0.19 | $-0.19 | $-0.18 | 4 |
| 2028-03-31 | $2.85 | $2.94 | $3.01 | 5 |
| 2028-06-30 | $1.70 | $1.75 | $1.80 | 7 |
| 2028-09-30 | $0.51 | $0.53 | $0.54 | 10 |
| 2028-12-31 | $-0.28 | $-0.27 | $-0.26 | 5 |
| 2029-12-31 | $6.99 | $7.28 | $7.55 | 1 |
| 2030-12-31 | $9.04 | $9.41 | $9.77 | 1 |
Frequently Asked Questions
What is the analyst consensus for CNC?
The consensus among 30 analysts covering Centene Corp. (CNC) is Buy with an average price target of $59.79.
What is the highest price target for CNC?
The highest price target for CNC is $109.00, set by Ricky Goldwasser at Morgan Stanley on 2021-12-17.
What is the lowest price target for CNC?
The lowest price target for CNC is $33.00, set by Andrew Mok at Barclays on 2025-09-04.
How many analysts cover CNC?
30 analysts have issued ratings for Centene Corp. in the past 12 months.
Is CNC a buy or sell right now?
Based on 30 analyst ratings, CNC has a consensus rating of Buy (2.50/5) with a +3.1% upside to the consensus target of $59.79.
What are the earnings estimates for CNC?
Analysts estimate CNC will report EPS of $3.02 for the period ending 2026-12-31, with revenue estimated at $188.83B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.